Citryll Doses First Patient in Phase IIa Hidradenitis Suppurativa Trial for CIT-013
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Should l Buy CITR?
Source: Globenewswire
- Trial Initiation: Citryll has commenced its Phase IIa clinical trial for CIT-013 targeting moderate to severe hidradenitis suppurativa in Oss, Netherlands, with the first patient dosed, marking a significant advancement in treating immune-mediated inflammatory diseases.
- Patient Cohort Size: The trial will enroll 96 participants over a 12-week period to assess the efficacy, safety, and tolerability of CIT-013, addressing a critical gap in treatment options currently available for this condition.
- Advisory Board Formation: Citryll has established a Clinical Advisory Board comprising global dermatology experts to provide strategic guidance throughout the trial, enhancing the company’s credibility and expertise in the field.
- Innovative Treatment Mechanism: As the first monoclonal antibody targeting extracellular traps, CIT-013 features a unique dual mechanism of action that may offer more effective treatment options for hidradenitis suppurativa and other inflammatory diseases, positioning the company for long-term growth in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CITR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CITR
About CITR
General Enterprise Ventures, Inc. is a flame retardant and flame suppression company for the residential home industry. The Company's products include MFB31- CitroTech, which is utilized in wildfire defense, and MFB34-CitroTech, which is used to treat lumber to inhibit fire and mold. It is developing a coating to treat lumber during manufacture prior to distribution. The Company holds various intellectual property in the form of patents and trademarks in the fields of fire suppression, mapping and tracking of fire-retardant dispersion and fire inhibition chemistry and technology. Its products are used in the residential home industry, including individual homeowners, developers and other third parties. The Company installs systems to deploy its product remotely to provide a buffer zone around properties to prevent combustion.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Strategic Relocation: CitroTech has relocated its headquarters to Denver South, leveraging the region's innovation hub and talent pool to accelerate the global deployment of environmentally-friendly fire protection solutions, thereby enhancing its competitive edge in a rapidly growing market.
- Surging Market Demand: Colorado is one of the most wildfire-prone states in the U.S., with approximately 2.5 million residents living in high-risk areas, and CitroTech's new headquarters will enable it to respond more effectively to this urgent market demand, driving sales growth of its eco-friendly fire prevention products.
- Infrastructure Advantages: The Denver South area boasts over 48 million square feet of office space and a robust transportation network, which CitroTech will utilize to accelerate product development and market outreach, further solidifying its leadership position in the environmental fire protection sector.
- Executive Appointment: Kevin Schaff has been appointed as the new Vice President of Business Development, tasked with leading sales and marketing initiatives from the Denver office, marking an expansion of the company's leadership in the region and strengthening its ties to the local economy.
See More
- Investor Conference Participation: CitroTech Inc. will participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10-11, 2026, where CEO Wes Bolsen will present at 1:00 PM ET on March 10, showcasing innovations in fire prevention solutions for wood products.
- One-on-One Investor Meetings: On the second day of the conference, CitroTech will engage in one-on-one meetings with pre-qualified investors, which not only helps strengthen relationships with potential investors but may also lead to new funding opportunities and market expansion.
- Eco-Friendly Fire Solutions: CitroTech is the only EPA Safer Choice recognized fire inhibitor in the U.S., focusing on manufacturing and deploying environmentally safe fire prevention solutions that meet UL Greenguard Gold standards, demonstrating its commitment to safety and environmental health.
- Long-Term Growth Potential: The company's growing patent portfolio and recurring revenue model, combined with its scalable approach, support CitroTech's long-term growth and market expansion strategy, enhancing its competitive position in the fire prevention industry.
See More
- Strong Banking Sector Performance: Banking and savings stocks collectively rose by approximately 3.1%, indicating a renewed market confidence in the financial sector, which may attract more investor interest in this area.
- ServisFirst Bancshares Leads Gains: ServisFirst Bancshares saw its stock price increase by about 13.1%, making it one of the best performers of the day, reflecting strong market performance and positive investor sentiment.
- Dime Community Bancshares Follows Suit: Dime Community Bancshares' stock rose by approximately 12.4%, indicating significant market recognition for the company in the competitive banking industry, potentially driving its future growth prospects.
- Industry Trend Analysis: With the strong rebound in banking stocks, investors may reassess investment opportunities in the financial sector, especially against the backdrop of economic recovery, where banking profitability is expected to further improve.
See More

- Trial Initiation: Citryll has commenced its Phase IIa clinical trial for CIT-013 targeting moderate to severe hidradenitis suppurativa in Oss, Netherlands, with the first patient dosed, marking a significant advancement in treating immune-mediated inflammatory diseases.
- Patient Cohort Size: The trial will enroll 96 participants over a 12-week period to assess the efficacy, safety, and tolerability of CIT-013, addressing a critical gap in treatment options currently available for this condition.
- Advisory Board Formation: Citryll has established a Clinical Advisory Board comprising global dermatology experts to provide strategic guidance throughout the trial, enhancing the company’s credibility and expertise in the field.
- Innovative Treatment Mechanism: As the first monoclonal antibody targeting extracellular traps, CIT-013 features a unique dual mechanism of action that may offer more effective treatment options for hidradenitis suppurativa and other inflammatory diseases, positioning the company for long-term growth in the biopharmaceutical sector.
See More







